Latest News

(UroToday.com) In this abstract presented by Alexander Kenigsberg and colleagues, at the American Urologic Association (AUA) annual meeting, the authors evaluated the usage of intravesical chemotherapy in the perioperative setting following radical nephroureterectomy for upper tract urothelial carcinoma. While utilization remains low, they note that usage is increasing worldwide.

(UroToday.com) In this study by Kaushik and colleagues, the authors explored the impact of yoga on men with newly diagnosed prostate cancer before and after prostatectomy. They found that yoga has important effects on quality of life (QoL), antitumor immune response, and inflammatory response.

(UroToday.com) In this presentation at the American Urologic Association (AUA) annual meeting, Dr. Kelly Stratton presents the initial results of the ABC trial, an open-label Phase Ib trial of BCG therapy in conjunction with avelumab for patients with BCG unresponsive non-muscle invasive bladder cancer (NMIBC). From a safety standpoint, they found that induction therapy with […]

(UroToday.com) In this late breaking abstract, Zhao and colleagues delved into the reporting of tobacco use in contemporary GU clinical trials and found that it is rarely collected or reported. Considering the impact of smoking on the development of GU malignancies, this is a deficiency that needs to be addressed.

(UroToday.com) In this abstract by Max Kates and colleagues, they report on the safety and preliminary efficacy of a large surface area microparticle docetaxel (LSAM-DTX) for the treatment of patients with AUA high-risk non-muscle-invasive bladder cancer (NMIBC).

Alicia Morgans: Hi, my name is Alicia Morgans and I’m a GU Medical Oncologist at Dana-Farber Cancer Institute. I’m so excited to have here with me today, a good friend and colleague, Dr. Neal Shore, who is the Medical Director for the Carolina Urologic Research Center in Myrtle Beach. Thank you so much for being […]

Alicia Morgans: Hi, my name is Alicia Morgans and I’m a GU Medical Oncologist at Dana Farber Cancer Institute in Boston, in the United States. I’m so excited to have here with me today, a good friend and colleague, Dr. Fred Saad, who is a Professor and Chief of Urology and the Director of GU […]

Post-hoc analysis shows that ERLEADA® provides rapid, deep, and durable PSA declines in advanced prostate cancer, with depth and speed of response correlating to improved  overall survival Real-world data demonstrate that, across racial groups, patients prescribed ERLEADA® for non-metastatic castration-resistant prostate cancer stay on therapy San Francisco, CA (UroToday.com) — The Janssen Pharmaceutical Companies of Johnson & Johnson […]

(UroToday.com) The plenary session at the 2021 AUA virtual annual meeting included the European Association of Urology lecture by Dr. Alberto Briganti who discussed clinically relevant questions in the management of locally advanced and oligometastatic prostate cancer.

(UroToday.com) In this presentation by Drs. Michael Gorin and Steven Rowe, the speakers provide a thorough, comprehensive overview of PSMA-targeted PET Imaging within the field of urology, with an emphasis on what Urologists need to know. While the focus is primarily on prostate cancer, they do briefly touch on the role of this novel technology for […]